期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

弥漫性大B细胞淋巴瘤预后因素的研究进展

Prognostic factors of diffuse large B cell iymphoma:an update
下载PDF
导出
摘要 弥漫性大B细胞淋巴瘤(diffuse large B cell lymphema,DLBCL)在形态学、临床表现及其治疗反应上都表现出异质性,明确DLBCL的预后影响因素有利于实施个体化治疗。根据免疫表型分组,DLBCL分为GCB组和非GCB组,GCB组患者预后明显优于非GCB组,其分组的准确性甚至优于基因检测;相关免疫表型如bcl-2、bcl-6对于不同组的预后影响不同,利妥昔单抗的应用减少了细胞来源和相关免疫表型对于预后的不良影响。特定转录因子可以作为预后预测因子,如FOXP1阴性组预后好于阳性组、LMO2高表达的患者具有较高生存率等。抑制PI3K/AKT通路可使淋巴瘤细胞发生凋亡,且p-AKT阴性组预后较阳性组好。谷胱甘肽过氧化物酶1(GXP1)低表达组预后较好;而在GXP1低表达组中,ABC转运体MDR1低表达组预后明显好于高表达组。此外,EB病毒感染、骨髓浸润的一致性、肿瘤大小、肿瘤血管形成均同预后有关,都有可能作为预后预测因子。
作者 林之光 许小平
机构地区 复旦大学附属华山医院血液科
出处 《中国肿瘤生物治疗杂志》 CAS CSCD 2008年第6期594-597,共4页 Chinese Journal of Cancer Biotherapy
基金 国家自然科学基金资助项目(No.39770330)~~
关键词 弥漫性大B细胞淋巴瘤 分型 预后 影响因素
分类号 R733.4 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1Haarer CF, Robers RA, Frutiger YM, et al. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B cell lymphoma into germinal center B cell and nongerminal center B cell subtypes correlates with gene expression profile and patient survival[J]. Arch Pathol Lab Med, 2006,130(12) : 1819-1824.
  • 2Moskowits CH, Zelenetz AD, Kewairamani T, et al. Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL[J]. Blood, 2005, 106(10) :3382-3385.
  • 3van Imhoff GW, Bierma E J, van der Holt B, et al. Prognostic impact of germinal center associated proteins and chromosomal breakpoints in poor risk diffuse large B cell lymphoma [ J ]. J Clin Oncol, 2006, 24(25) :4135-4142.
  • 4Iqbal J, Neppalli VT, Wright G, et al. Bcl-2 expression is a prognostic marker of the activated B cell like type of diffuse large B cell lymphoma[J].J Clin Oncol, 2006, 24(7) :961-968.
  • 5Mainou-Fowler T, Overman LM, Dignum H, et al. A new subtype-specific monoclonal antibody for IAP-survivin identifies highrisk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2[J]. Int J Oncol, 2008, 32( 1) :59-68.
  • 6Chen YW, Hu XT, Liang AC, et al. High bcl-6 predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lympboma [J]. Blood, 2006, 108(7): 2372-2383,
  • 7Nyman H, Adde M, Karjalainen-Lindsberg M, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B cell lymphoma patients treated with immunochemotherapy[J]. Blood, 2007, 109 ( 11 ) :4930-4935.
  • 8Winter JN, Weller EA, Homing SJ, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study [ J ]. Blood, 2006, 107 ( 11 ) :4207-4213.
  • 9Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B- cell lymphoma with analysis of germinal center and post-germinal center biomarkers[J]. J Clin Oncol, 2008, 26(16) :2717-2124.
  • 10Banham AH, Connors JM, Brown PJ, et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B cell lymphoma [ J ]. Clin Cancer Res, 2005, 11 (3) :1065-1072.
中国肿瘤生物治疗杂志
2008年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部